CB 001Alternative Names: CB-001
Latest Information Update: 13 Feb 2007
At a glance
- Originator ViaCell
- Class Cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Haematological malignancies